ДЗЕ ЮНИВЕРСИТИ ОФ НОРТ КАРОЛИНА ЭТ ЧЕПЕЛ ХИЛЛ (US)
发明人:
КЛЕММОНС Дэвид Р. (US),МЭЙЛ Лаура А. (US)
申请号：
RU2014111472/10
公开号：
RU2014111472A
申请日:
2012.08.24
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A monoclonal antibody that specifically binds an epitope consisting of amino acids 71-80 of the human IAP protein and is an antagonist of the binding of IAP to SHPS-1.2. The antibody according to claim 1, associated with a detectable group. The antibody according to claim 1, associated with a therapeutic group. The antibody according to claim 1, characterized in that the antibody does not destroy the binding of IAP to β.5 protein. A pharmaceutical composition comprising the antibody of claim 1 in a pharmaceutically acceptable carrier. The antibody according to claim 1, wherein the antibody is selected from the group consisting of (a) a monoclonal antibody produced by the NPG-1 hybridoma, and (b) a monoclonal antibody that competes for binding to the same epitope as the epitope to be bound monoclonal antibody produced by NPG-1.7 hybridoma. The antibody according to claim 6, associated with the detected group. The antibody according to claim 6, associated with a therapeutic group. A pharmaceutical composition comprising the antibody of claim 6 in a pharmaceutically acceptable carrier. A method of inhibiting the action of IGF-1 in an individual in need thereof, comprising administering to the individual the antibody of claim 11.11. A method of inhibiting the action of IGF-1 in an individual in need thereof, comprising administering to the individual the antibody of 6.12. A method for treating retinopathy in an individual, comprising administering to the individual an effective amount of an antibody according to claim 1 or 6.13. A method for treating atherosclerosis in an individual, comprising administering to the individual an effective amount of an antibody according to claim 1 or 6.14. A method for treating nephropathy in an individual, comprising administering to the individual an effective amount of an antibody according to claim 1 or 6.15. A method for the treatment of coronary heart disease in an individual, including iv1. Моноклональное антитело, которое спе
